<DOC>
	<DOCNO>NCT03084640</DOCNO>
	<brief_summary>CMP-001-002 Phase 1b study CMP-001 administer either subcutaneously ( SC ) intratumorally ( IT ) follow subsequent SC administration , combination Pembrolizumab subject advanced cutaneous melanoma either receive Pembrolizumab , previously receive anti-PD-1/PD-L1 therapy advance cutaneous melanoma , respond ( i.e . immunotherapy resistant ) . This study conduct two part : Part 1 consist Dose Escalation Phase Dose Expansion Phase CMP-001 - Dose Escalation Phase conduct assess identify recommend phase 2 dose ( RP2D ) SC administration . - The Dose Expansion Phase intend characterize safety , pharmacodynamics , preliminary evidence antitumor activity RP2D CMP-001 administer SC combination Pembrolizumab . Part 2 ass safety preliminary evidence antitumor activity CMP-001 , administer IT 3 weekly dos , follow CMP-001 SC dose every 3 week ( q3wk ) , give combination Pembrolizumab .</brief_summary>
	<brief_title>Phase 1b Study Evaluating Alternative Routes Administration CMP-001 Combination With Pembrolizumab Subjects With Advanced Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Subjects enrol Part 1 must metastatic lesion repeat IT injection feasible SC injection viable route CMP001 administration , base Investigator judgment . Subjects injectable lesion NOT eligible participate Part 1 . Subjects enrol Part 2 must metastatic lesion amenable repeat IT injection . All subject enrol either Part 1 Part 2 must meet follow inclusion criterion eligible : Histopathologically confirm diagnosis metastatic malignant melanoma arise skin . Ocular melanoma subject eligible . Male female subject age 18 old 1 . Currently receive treatment antiPD1 antibody Pembrolizumab either alone combination . Subjects must either Stable Disease ( SD ) Progressive Disease ( PD ) per RECIST Version 1.1 Pembrolizumab . Subjects SD must Pembrolizumab least 12 week . There minimum treatment duration subject PD Pembrolizumab . OR 2 . Subjects previously receive antiPD1/PDL1 therapy , alone combination , deem respond therapy/combination irrespective timing prior therapy relative first dose CMP001 . Subjects must measurable disease RECIST Version 1.1 . Capable understand comply protocol requirement . A life expectancy great 24 week Screening . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Most recent laboratory value ( within 2 week prior Week 1 Day 1 ( W1D1 ) ) study entry meet following standard : 1 . Bone marrow function : neutrophil count &gt; /=1,000/mm3 , platelet count &gt; /= 75,000/mm3 hemoglobin concentration &gt; /= 8.0 g/dL . 2 . Liver function : total bilirubin ≤ 1.5 time upper limit normal ( ULN ) institution , aspartate aminotransferase alanine aminotransferase ≤ 3 time ULN range institution . 3 . LDH ≤2.0 time ULN range institution 4 . Renal function : serum creatinine ≤1.5 time ULN range institution . The subject subject 's legally acceptable representative must sign write informed consent form prior initiation study procedure . Pregnant breast feeding . Received investigational therapy another drug biologic within 30 day prior start CMP001 dose W1D1 . However , investigational drug short halflife , short wash period may acceptable upon permission give Sponsor . Received treatment antiCTLA4 antibody within 30 day prior start CMP001 dose W1D1 . Known infection human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) . Developed autoimmune disorder Grade 4 prior immunotherapy . Subjects develop autoimmune disorder Grade ≤ 3 may enroll disorder resolve Grade ≤1 subject systemic steroid least 2 week . Subjects experience autoimmune colitis toxicity prior immunotherapy must undergo screen colonoscopy rule ongoing inflammation documentation colitis resolve ( i.e . prior colonoscopy ) . Require systemic pharmacologic dos corticosteroids equivalent 10 mg/d prednisone ; replacement dos , topical , ophthalmologic inhalational steroid permit . Active ( i.e. , symptomatic grow ) central nervous system ( CNS ) metastases . Subjects CNS metastases eligible trial metastasis treat surgery and/or radiotherapy , subject corticosteroid neurologically stable least 2 week prior Screening . Any concurrent uncontrolled illness , include mental illness substance abuse , opinion Investigator , would make subject unable cooperate participate trial . Severe uncontrolled cardiac disease within 6 month study entry , include limited uncontrolled hypertension ; unstable angina ; myocardial infarction ( MI ) cerebrovascular accident ( CVA ) . Requires prohibit treatment ( i.e. , nonprotocol specify anticancer pharmacotherapy , surgery conventional radiotherapy treatment malignant tumor ) . Women childbearing potential unable unwilling use acceptable method contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>